BACKGROUND: In spite of cost-saving tobacco-dependence treatments, many state Medicaid programs offer only limited coverage for these treatments. This report builds a case for state-level financial benefits from funding smoking cessation treatment for Medicaid-eligible populations. METHODS: Applying published cost estimates to state-specific data, we assessed potential health care savings from tobacco-dependence treatments for pregnant women, mothers exposing young children to secondhand smoke, and other adult Medicaid beneficiaries. RESULTS: Across all three populations there was evidence for short-term positive returns on investment. Including counseling and nicotine replacement therapy, estimated net savings were $157,000 annually for pregnant women and their newborns, $33,000 annually within four years for children exposed to smoke at home, and $5 million annually within two years for the general adult Medicaid population in Alabama. CONCLUSIONS: Findings suggest that making tobacco-dependence treatment freely available to low-income smokers can produce net savings for state governments within a short period of time.
No takes yet. Share an insight, caveat, or question.
McCallum et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: